Clinical trials: Lymphatic System Neoplasm
Leukemia
Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug and giving them as induction intensification may kill more…
- Trial name
- NCT00002756
- Testing
- filgrastim, asparaginase, cyclophosphamide
- Where
- 140 sites in United States, Australia and 2 more
- Volunteers
- 221 people
- Sponsor
- Children's Oncology Group
Hematologic Malignancies, Leukemia
Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
Primary objective: To determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of TCN-PM (Triciribine) when administered as an approximately one-hour intravenous infusion on a weekly schedule on days 1, 8 and…
- Trial name
- NCT00642031
- Testing
- Triciribine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Prescient Therapeutics, Ltd.
Lymphoma, Leukemia
Phase I Study of Sequential Cord Blood Transplants
The purpose of this study is to determine the safety of sequential cord blood transplantation (2 cord blood units) for patients who have diseases that are capable of being cured by allogeneic stem cell transplant but do not have…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
- Trial name
- NCT00299767
- Testing
- sequential cord blood transplantation
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
B-Cell Lymphoblastic Leukemia/Lymphoma
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD22 bispecific CAR-T cells in relapsed /…
- Trial name
- NCT06735495
- Testing
- CD19&CD22 bispecific CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Ph^1^, Absent
Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
The cure rate for childhood acute lymphoblastic leukemia (ALL) has increased significantly in recent decades and expected cure rates now exceed 85%.
- Conditions
- Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Ph^1^, Absent, B-cell Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT01990807
- Testing
- Idarubicin(IDA)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
Brain Stem Neoplasm, Pineal Region Neoplasm
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment.
- Conditions
- Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02780804
- Testing
- Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 21 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML
This is a Phase I, multi-center, open-label, dose escalation, MTD study of liposomal annamycin in children and young adults with refractory or relapsed ALL or AML.
- Trial name
- NCT00430443
- Testing
- Liposomal Annamycin
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Callisto Pharmaceuticals
Lymphoma
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
The purpose of this study is to find out if immunotherapy (rituximab) added to chemotherapy is a safe treatment for primary central nervous system lymphoma (PCNSL). PCNSL is a rare tumor.
- Trial name
- NCT00594815
- Testing
- Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
AML, ALL
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic…
- Conditions
- AML, ALL, MDS, MPD Withou Myelofibrosis
- Trial name
- NCT04644016
- Testing
- Clofarabine, Fludarabine, Busulfan
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hemangioma
Topical Timolol Gel for the Treatment of Infantile Hemangiomas
We plan to conduct a study, to see how safe and effective timolol maleate 0.5% gel-forming solution is for infantile hemangiomas (IH) and the response of hemangiomas to timolol maleate 0.5% .
- Trial name
- NCT02145884
- Testing
- timolol maleate 0.5% gel
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rady Children's Hospital, San Diego
Leukemia, Graft-versus-host-disease
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
A single-arm trial using Tocilizumab for acute GVHD prophylaxis after haploidentical HSCT.
- Trial name
- NCT04688021
- Testing
- Cytarabine, Busulfan, Cyclophosphamide
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Yi Luo
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
In this study the investigators investigate a cell therapy strategy that could harness allogeneic effectors that can potentially mediate anti-lymphoma effect.
- Trial name
- NCT01181258
- Testing
- Rituximab, Interleukin-2, Natural killer cells
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home
This clinical trial tests different programs to help patients with acute lymphoblastic leukemia (ALL) remember to take their medications during maintenance therapy at home.
- Trial name
- NCT06639958
- Testing
- Biospecimen Collection, Compliance Monitoring, Health Promotion and Education
- Where
- 27 sites in United States
- Volunteers
- 64 people
- Sponsor
- Children's Oncology Group
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT
The purpose of this prospective, open-label, single-center study is to evaluate the efficacy and safety of VEN-AZA (venetoclax and azacytidine) followed by modified BUCY (busulfan and cyclophosphamide) as conditioning regimen for…
- Trial name
- NCT05809167
- Testing
- VEN+AZA+Modified BUCY
- Where
- China
- Volunteers
- 55 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Cytarabine+Thiotepa + Fludarabine + Busulfan, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL
T cell acute lymphoblastic leukemia (T-ALL)/Lymphoblastic lymphoma (LBL) is a hematological malignancy caused by malignant transformation and clonal expansion of T-lineage precursor cells.
- Trial name
- NCT05598593
- Testing
- cytarabine+thiotepa+ fludarabine + busulfan
- Where
- China
- Volunteers
- 70 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Building upon the results from the CCCG-ALL-2015, CCCG-ALL-2020 multicenter study cohort, concurrent research findings, and the latest clinical trials, the CCCG-ALL-2025 I/HR-B-ALL is thus developed to further improve the…
- Conditions
- Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
- Trial name
- CCCG-I/HR-ALL (NCT06764238)
- Testing
- Blinatumomab (Group A), Venetoclax (nonRand Group), Blinatumomab (Group B)
- Where
- 27 sites in China, Hong Kong
- Volunteers
- 1,800 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Health Care Utilisation Among Survivors of Childhood Acute Lymphoblastic Leukaemia
Improved understanding of the long-time healthcare utilisation of childhood cancer survivors is relevant as it can be seen as a proxy for the population's morbidity.
- Trial name
- NCT03985826
- Testing
- Diagnosis of and treatment for Acute lymphoblastic leukaemia in childhood
- Where
- Denmark
- Volunteers
- 7,348 people
- Sponsor
- University of Aarhus
Lymphatic Malformations
Bleomycin Intralesional Injections of Cystic Hygromas
Thirty pediatric patients with cystic hygromas participated in this study. The cystic fluid was aspirated from the cystic hygroma, and the lesion was simultaneously injected with Bleomycin.
- Trial name
- NCT07189832
- Testing
- Intralesional Injections
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Delta University for Science and Technology
Leukemia, Lymphoma
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Background: Leukapheresis is a procedure to separate and collect white blood cells. It is the first step in a treatment called CAR (chimeric antigen receptor) T-cell therapy.
- Conditions
- Leukemia, Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03226704
- Testing
- Leukapheresis
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900484
- Testing
- biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 191 sites in United States
- Volunteers
- 458 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.